Durable responses to erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma

Annals of Oncology

Volumn 21, Issue 6, 2010, Pages 1385-1387

  Ferte C ^a,b   Besse, B ^a   Dansin, E ^b   Parent, F ^c   Buisine, M P ^d   Copin, M C ^d   Penel, N ^b   Soria, J C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE B; RNA; SPROUTY PROTEIN; STAT PROTEIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; QUINAZOLINE DERIVATIVE; RAS PROTEIN;

ALTERNATIVE RNA SPLICING; CASE REPORT; CHEMOSENSITIVITY; CIGARETTE SMOKING; GENE MUTATION; GENETIC VARIABILITY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; PATIENT SELECTION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN PROCESSING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VOLUME; WILD TYPE; ADENOCARCINOMA; GENETICS; LUNG NEOPLASMS; METASTASIS; MUTATION; PATHOLOGY; PHYSIOLOGY; REMISSION; TIME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; REMISSION INDUCTION; TIME FACTORS;

EID: 77954012635     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq153     Document Type: Letter

References (22)

1. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2(1): e17.
2. Fujimoto N, Wislez M, Zhang J et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005; 65(24): 11478-11485.
3. Ichihara S, Toyooka S, Fujiwara Y et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 2007; 120(6): 1239-1247.
4. Han SW, Kim TY, Jeon YK et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006; 12(8): 2538-2544.
5. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13(10): 2890-2896.
6. van Zandwijk N, Mathy A, Boerrigter L et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro-and prospective observations in non-small-cell lung cancer. Ann Oncol 2007; 18(1): 99-103.
7. Schneider CP, Heigener D, Schott-von-Römer K et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008; 3(12): 1446-1453.
8. Varella-Garcia M, Mitsudomi T, Yatabe Y et al. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 2009; 4(3): 318-325.
9. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12(20 Pt 1): 16049-16055.
10. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24(31): 5034-5042.
11. Hirsch FR, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18(4): 752-760.
12. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapynaive patients > or = 70 years of age treated with erlotinib for advanced nonsmall-cell lung cancer. J Clin Oncol 2007; 25(7): 760-766.
13. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26(26): 4268-4275.
14. Miller VA, Riely GJ, Zakowski MF et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26(9): 1472-1478.
15. Felip E, Rojo F, Reck M et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008; 14(12): 3867-3874.
16. D'Addario G, Rauch D, Stupp R et al. Multicenter phase II trial of gefitinib firstline therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008; 19(4): 739-745.
17. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessmentofsomatick-RASmutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9(10): 962-972.
18. Pirker R, Su W, Rooneem R et al. Clinical outcomes with erlotinib in relation to biomarker status: analyses from the open label TRUST study in advanced nonsmall cell lung cancer. Ann Oncol 2008; 19 (Suppl 8): viii100.
19. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated nonsmall cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15: 5267-5273.
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132.
21. Lee CN, Chen HY, Liu HE. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations. J Clin Oncol 2010; 28(7): e111-112.
22. Singh A, Greninger P, Rhodes D et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009; 15(6): 489-500.